Emily Hansen
YOU?
Author Swipe
View article: Continuity Is Essential: The Experiences of Co‐Design Participants During the Implementation of a New Health Service
Continuity Is Essential: The Experiences of Co‐Design Participants During the Implementation of a New Health Service Open
Objective To explore the experiences of participants in the co‐design of a community‐based health service for people with frequent hospital admissions with regard to the design process and its outcomes. Study Setting and Design Qualitative…
View article: Correction: Emerin deficiency drives MCF7 cells to an invasive phenotype.
Correction: Emerin deficiency drives MCF7 cells to an invasive phenotype. Open
View article: Emerin expression stratification across breast cancer subtypes
Emerin expression stratification across breast cancer subtypes Open
Nuclear dysmorphism is a critical indicator of tumor aggressiveness, influencing cancer cell invasion and metastasis. Emerin, an integral nuclear envelope protein involved in nuclear architecture, is important for maintaining nuclear integ…
View article: Young mothers’ experiences of maternity care: A synthesis of qualitative research
Young mothers’ experiences of maternity care: A synthesis of qualitative research Open
Young mothers face many challenges during their maternity care journey. Identifying the young person's social and cultural care needs and building positive relationships with care providers will improve their experiences. Research is urgen…
View article: Emerin expression stratification across breast cancer subtypes
Emerin expression stratification across breast cancer subtypes Open
Nuclear dysmorphism is a critical indicator of tumor aggressiveness, influencing cancer cell invasion and metastasis. Emerin, an integral nuclear envelope protein involved in nuclear architecture, is important for maintaining nuclear integ…
View article: Fathers’/male partner’s representation in breastfeeding policies: A content analysis of Australian and global infant feeding policies
Fathers’/male partner’s representation in breastfeeding policies: A content analysis of Australian and global infant feeding policies Open
Background: Fathers/male partners are known to be increasingly involved in caring for babies and young children and to be a valuable source of support for mothers in establishing and maintaining breastfeeding. Despite this, interventions a…
View article: Mothers' and fathers' experiences of breastfeeding and returning to paid work after birth: A mixed‐method study
Mothers' and fathers' experiences of breastfeeding and returning to paid work after birth: A mixed‐method study Open
This mixed‐method study explored the experiences of mothers and fathers combining breastfeeding with returning to paid employment after childbirth. Tasmanian State Service employees participated in an online survey and phone interviews. A …
View article: Emerin deficiency drives MCF7 cells to an invasive phenotype
Emerin deficiency drives MCF7 cells to an invasive phenotype Open
View article: Experiences of participants in the co-design of a community-based health service for people with high healthcare service use
Experiences of participants in the co-design of a community-based health service for people with high healthcare service use Open
Background Incorporating perspectives of health consumers, healthcare workers, policy makers and stakeholders through co-design is essential to design services that are fit for purpose. However, the experiences of co-design participants ar…
View article: Emerin deficiency drives MCF7 cells to an invasive phenotype
Emerin deficiency drives MCF7 cells to an invasive phenotype Open
During metastasis, cancer cells traverse the vasculature by squeezing through very small gaps in the endothelium. Thus, nuclei in metastatic cancer cells must become more malleable to move through these gaps. Our lab showed invasive breast…
View article: Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 297K, Survival outcomes in Total Therapy 2 according to randomization to control arm (-T) or thalidomide (+T).
View article: Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 256K, Thalidomide effect on overall and progression-free survival according to glucocorticoid receptor (NR3C1) expression level.
View article: Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
Purpose: Because dexamethasone remains a key component of myeloma therapy, we wished to examine the impact of baseline and relapse expression levels of the glucocorticoid receptor gene NR3C1 on survival outcomes in the contex…
View article: Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 142K, Effect of cumulative thalidomide dosing prior to start of maintence on OS and PFS, landmarked at start of maintence, for all patients.
View article: Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 94K, Post-relapse survival according to NR3C1 levels at baseline and at relapse.
View article: Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 56K, Salvage Regimen for 255 Patients with available data.
View article: Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 88K.
View article: Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure Legend from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 88K.
View article: Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 142K, Effect of cumulative thalidomide dosing prior to start of maintence on OS and PFS, landmarked at start of maintence, for all patients.
View article: Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 136K, Kaplan-Meier plots for overall survival from start of first salvage therapy.
View article: Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 256K, Thalidomide effect on overall and progression-free survival according to glucocorticoid receptor (NR3C1) expression level.
View article: Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 56K, Salvage Regimen for 255 Patients with available data.
View article: Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Data from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
Purpose: Because dexamethasone remains a key component of myeloma therapy, we wished to examine the impact of baseline and relapse expression levels of the glucocorticoid receptor gene NR3C1 on survival outcomes in the contex…
View article: Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 136K, Kaplan-Meier plots for overall survival from start of first salvage therapy.
View article: Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 5 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 94K, Post-relapse survival according to NR3C1 levels at baseline and at relapse.
View article: Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i> Open
PDF file, 297K, Survival outcomes in Total Therapy 2 according to randomization to control arm (-T) or thalidomide (+T).
View article: The nuclear envelope and metastasis
The nuclear envelope and metastasis Open
View article: Medical understandings of lifestyle : an interpretive study of 'lifestyle' as a medical explanatory framework
Medical understandings of lifestyle : an interpretive study of 'lifestyle' as a medical explanatory framework Open
This thesis provides an overview of lifestyle as a medical explanatory concept, explicating contemporary medical understandings of lifestyle and situating these within a wider social and historical framework. It argues that ideas about lif…
View article: Breastfeeding Multiples
Breastfeeding Multiples Open
How do women experience breastfeeding multiples? Given the rising rate of multiple births and the global public health target of increasing the number of women exclusively breastfeeding up to the first 6 months, it is imperative that we un…
View article: Navigating the maze of osteoarthritis treatment: A qualitative study exploring the experience of individuals with osteoarthritis in Tasmania, Australia
Navigating the maze of osteoarthritis treatment: A qualitative study exploring the experience of individuals with osteoarthritis in Tasmania, Australia Open
Objective Using a qualitative design this study aimed to (1) explore the experience of people living with osteoarthritis (OA), (2) gain an understanding of their navigation of the health system and, (3) explore their opinions on the role o…